FUJIFILM Diosynth Biotechnologies, Merck and
Pfizer to help Emerson develop standards for holistic digitalized
recipe platform to increase speed to market for life-saving
drugs
Emerson's new Life Science Technology Transfer
and Software Research Center to develop, verify
technology
AUSTIN,
Texas, Oct. 4, 2023 /PRNewswire/ -- Global
technology and software leader Emerson (NYSE: EMR) announced a
new executive board of key life sciences leaders to help define,
review and demonstrate prototypes for Emerson technologies that
will safely speed life-saving drugs to market.
Collaborating through Emerson's One-Click Technology Transfer™
Board, Emerson customers FUJIFILM Diosynth Biotechnologies,
Merck and Pfizer will lead the development of strategies,
solutions and guidelines to convert today's life sciences
manufacturing recipe transfer process into a digitalized production
platform. Digitalizing recipe technology transfer will reduce the
time, effort and risk of managing, sharing and translating
information to help get new drug therapies to patients faster.
Emerson will also open a dedicated research center to accelerate
the development of One-Click Technology Transfer software. Located
in the Singapore life sciences
manufacturing hub that is home to 8 of the 10 global pharmaceutical
companies, Emerson's new research center will design, develop and
verify the software and digitalized production platform.
"What we learned through the pandemic was that with
hyper-focused investment and coordination, new treatments can be
brought to market safely and also at warp speed," said Nathan Pettus, president of Emerson's process
systems and solutions business. "Bringing these key industry
leaders together – and dedicating a new research center to
advancing technology and standards – will help make the lessons
learned more systemic, accelerating the development pipeline and
safely supporting patients with life-saving and life-improving
treatments.
"This industry is highly regulated to ensure that lifesaving and
enriching medicines are of dependable and consistent quality,"
continued Pettus. "Emerson is proud to facilitate this
process of innovation with so many leading companies to drive
standards that will accelerate the adoption of new technologies and
performance benefits they bring."
Life sciences companies currently spend inordinate amounts of
time and money to move information – recipes, process sequences,
operating parameters, equipment characteristics, quality
requirements and more – among disparate applications and databases
including enterprise resource planning, process and knowledge
management, maintenance management, quality management and
automation systems.
Emerson's One-Click Technology Transfer capabilities will help
digitalize drug recipes and recipe management, from discovery and
development to production at scale, providing valuable translations
between drug recipe requirements and manufacturing processes while
establishing best practices and creating a framework to unify
disconnected systems into a holistic platform. The board will
define reference data models and objects for one-click
manufacturing, create the framework for a centralized recipe
transport and translation platform that is scalable and extensible,
and define and implement standards for version and quality control
while simultaneously ensuring the overall system is easy and
intuitive to use.
Emerson's Singapore Life Science Software Research
Center
Emerson's data scientists and software developers at
the research center will use the latest computer software
development technologies to perform rapid prototyping to test and
verify concepts. The software platform developed through rapid
prototyping will be tested and proven, working across the One-Click
Technology Transfer Board company supply chains as
appropriate.
The new board builds on Emerson's globally recognized life
sciences leadership combined with the industry's most flexible and
integrable solutions. Bolstered by its acquisition of the Fluxa
PKM™ solution and AspenTech's software capabilities including
AspenTech DataWorks industrial information management software,
Emerson is well positioned to develop the technologies and
standards for a fully integrated end-to-end solution for the drug
development pipeline.
"The life sciences industry is a very close-knit community and
ecosystem where successful solutions can rapidly spread and
completely alter the landscape," said Lars
Petersen, president and CEO of FUJIFILM Diosynth
Biotechnologies. "The generations of life sciences expertise in the
current partners of the One-Click Technology Transfer Executive
Board will help ensure successful digitalization solutions also
promote scalability, standardization and best practices as they
influence the coming decades of life sciences innovation and
benefits for patients."
"Our vision is to move from document driven processes to data
driven processes to accelerate our new product launch and
technology transfer," said Mike
Tomasco, vice president of Pfizer Digital Manufacturing.
"Life sciences commercial manufacturing requires significant
capital investment in facilities. One-click technology transfer
will help organizations determine facility fit to help teams move
more quickly, confidently and cost effectively from research and
development, through clinical trials, and into full-scale
manufacturing."
Additional resources:
- Join the Emerson Exchange 365 Community
- Connect with Emerson via Twitter Facebook LinkedIn YouTube
About Emerson
Emerson (NYSE: EMR) is a global
technology and software company providing innovative solutions for
the world's essential industries. Through its leading automation
portfolio, including its majority stake in AspenTech, Emerson helps
hybrid, process and discrete manufacturers optimize operations,
protect personnel, reduce emissions and achieve their
sustainability goals. For more information, visit Emerson.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/emerson-forms-life-sciences-executive-board-to-advance-one-click-technology-transfer-initiative-301945784.html
SOURCE Emerson